Group 1: Semiconductor Equipment Sector - ASML and other European semiconductor equipment stocks rose due to Samsung winning a contract to produce AI chips for Tesla, alongside a trade agreement between the US and Europe that alleviated trade war concerns [1] Group 2: AI and E-commerce - Alibaba International's AI solution Marco won the SAIL award, with external partners' AI usage increasing by 23 times [1] Group 3: Automotive Industry - South Korea's eco-friendly vehicle registrations surpassed 3 million for the first time, driven by demand for hybrid and electric vehicles, while internal combustion engine vehicle registrations decreased by 249,000 [3] - Lantu Automotive's registered capital increased from approximately 3.09 billion RMB to about 3.67 billion RMB, marking a 19% increase [6] Group 4: Investment and Financing - Moutai's fund and CITIC Securities invested in Leju Robotics, increasing its registered capital from about 1.9 million RMB to approximately 2.27 million RMB [4] - "Tangshangtang" completed a Pre-A round financing of several million RMB, with funds allocated for supply chain development and team building [5] Group 5: New Technologies and Products - A new wearable device developed by the Israel Institute of Technology can monitor blood sugar and drug concentration in real-time, applicable to various chronic diseases [7] - KUSAI Intelligent won the AI NAS frame project with Honor, expected to enter mass production in Q4 2025 [7] Group 6: Pharmaceutical Developments - Bristol-Myers Squibb's dual immunotherapy for non-small cell lung cancer received approval in China, providing a new treatment option without chemotherapy [8] Group 7: Economic Outlook - Bank Negara Malaysia revised its economic growth forecast for 2025 to 4% to 4.8%, down from 4.5% to 5.5%, citing trade and tariff uncertainties [10]

智通财经7月28日电，智通财经从百时美施贵宝获悉，其欧狄沃（纳武利尤单抗注射液）联合逸沃（伊 匹木单抗注射液）方案获国家药品监督管理局（NMPA）批准，适用于由国家药监局批准的检测评估为 PD-L1肿瘤比例分数（TPS）≥1%的表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶 （ALK）阴性的转移性非小细胞肺癌一线治疗。该联用疗法是中国首个获批的肺癌双免疫联合疗法， 为前述适应证患者提供了无化疗的长生存新选择。 (智通财经记者 陈杨) 百时美施贵宝获批中国首个非小细胞肺癌一线双免疫疗法 ...